We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Urinary Aquaporin 2 Excretion After Methylprednisolone in Fasting Healthy Humans

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00281710
First Posted: January 25, 2006
Last Update Posted: May 9, 2008
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Regional Hospital Holstebro
  Purpose
We wanted to test the hypotheses that methylprednisolone up regulates u-AQP-2 in fasting healthy humans

Condition Intervention Phase
Healthy Drug: Methylprednisolone Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single
Official Title: Urinary Aquaporin 2 Excretion After Methylprednisolone in Fasting Healthy Humans

Resource links provided by NLM:


Further study details as provided by Regional Hospital Holstebro:

Primary Outcome Measures:
  • u-AQP-2
  • FeNa+

Estimated Enrollment: 20
Study Start Date: October 2005
Study Completion Date: February 2007
Primary Completion Date: February 2007 (Final data collection date for primary outcome measure)
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • (1) Genders; both mal and female
  • (2) Age; 18- 65 years old
  • (3) BMI; below 30
  • (4) Females had to bee in oral contraceptive treatment

Exclusion Criteria:

  • (1) Clinical signs or history of disease in the heart, lungs, kidneys or endocrine organs
  • (2) Abnormal laboratory test (blood haemoglobin, white cell count, platelets, plasma sodium, plasma potassium, plasma creatinine, plasma albumin, plasma bilirubin, plasma alanine aminotransferase, plasma cholesterol and blood glucose)
  • (3) Albuminuria or glucosuria
  • (4) Cancer
  • (5) Arterial hypertension
  • (6) Alcohol abuse
  • (7) Use of tobacco
  • (8) Medical treatment, except oral contraceptives
  • (9) Pregnancy or breast feeding
  • (10) Medicine abuse
  • (11) Donation of blood less than 1 month before the study.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00281710


Locations
Denmark
Department of Medicine, Holstebro Hospital
Holstebro, Denmark
Sponsors and Collaborators
Regional Hospital Holstebro
Investigators
Study Chair: Erling B Pedersen, Professor Holstebro Hospital, 7500 Holstebro, Denmark
Principal Investigator: Thomas G Knudsen, MD Holstebro Sygehus
  More Information

ClinicalTrials.gov Identifier: NCT00281710     History of Changes
Other Study ID Numbers: MED.RES.HOS.2005.02.TGK
First Submitted: January 23, 2006
First Posted: January 25, 2006
Last Update Posted: May 9, 2008
Last Verified: May 2008

Keywords provided by Regional Hospital Holstebro:
AQP-2
Methylprednisolone
Urinary concentrating ability

Additional relevant MeSH terms:
Prednisolone acetate
Methylprednisolone acetate
Methylprednisolone
Methylprednisolone Hemisuccinate
Prednisolone
Prednisolone hemisuccinate
Prednisolone phosphate
Anti-Inflammatory Agents
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Neuroprotective Agents
Protective Agents
Antineoplastic Agents, Hormonal
Antineoplastic Agents